Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its position in Exact Sciences Corporation (NASDAQ:EXAS) by 77.8% during the third quarter, HoldingsChannel reports. The firm owned 5,581 shares of the medical research company’s stock after selling 19,557 shares during the period. Fox Run Management L.L.C.’s holdings in Exact Sciences were worth $305,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Great Lakes Advisors LLC boosted its position in Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock worth $215,000 after acquiring an additional 178 shares during the last quarter. Capital Asset Advisory Services LLC raised its holdings in Exact Sciences by 4.8% in the 3rd quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company’s stock valued at $216,000 after acquiring an additional 182 shares during the last quarter. Assetmark Inc. lifted its stake in Exact Sciences by 7.2% in the 3rd quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock worth $196,000 after purchasing an additional 242 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in shares of Exact Sciences by 100.0% during the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after purchasing an additional 271 shares during the last quarter. Finally, Crestwood Advisors Group LLC boosted its holdings in shares of Exact Sciences by 6.8% during the 2nd quarter. Crestwood Advisors Group LLC now owns 5,149 shares of the medical research company’s stock worth $274,000 after purchasing an additional 328 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on EXAS shares. Wall Street Zen cut Exact Sciences from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Wells Fargo & Company restated an “equal weight” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a report on Thursday, January 22nd. Craig Hallum cut shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price target on the stock. in a research report on Friday, November 21st. Finally, Stifel Nicolaus restated a “hold” rating and set a $105.00 price objective (up from $80.00) on shares of Exact Sciences in a research report on Friday, November 28th. Twenty-one investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $92.13.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $103.35 on Tuesday. The stock has a fifty day simple moving average of $102.51 and a 200-day simple moving average of $80.50. The company has a current ratio of 2.43, a quick ratio of 2.17 and a debt-to-equity ratio of 0.97. The stock has a market cap of $19.73 billion, a PE ratio of -93.95, a P/E/G ratio of 2.35 and a beta of 1.41. Exact Sciences Corporation has a twelve month low of $38.81 and a twelve month high of $103.67.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.06) earnings per share. Equities analysts anticipate that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.